Glenmark Pharmaceuticals to Directly Commercialize RYALTRIS® in the U.S.
Elmwood Park, New Jersey, April 01, 2026 – Glenmark Pharmaceuticals Inc., USA (Glenmark) announced it will manage end-to-end commercialization and distribution for RYALTRIS® (Olopatadine Hydrochloride and Mometasone Furoate) Nasal Spray, 665 mcg/25 mcg* per spray in the United States, effective April 1, 2026.This marks a step in Glenmark’s expansion in the region with a focus on building a direct commercial presence in the U.S. RYALTRIS® is Glenmark’s first innovative product introduced into the U.S. market and was initially launched in the United States in 2022. It is approved by the U.S. Food and Drug Administration (U.S. FDA) for treating Seasonal Allergic Rhinitis (SAR) in adults and paediatric patients 12 years of age and older. The product is a fixed-dose combination nasal spray combining olopatadine hydrochloride and mometasone furoate.
Glenmark will directly lead brand strategy, market access, and customer engagement for RYALTRIS® in the U.S., allowing for focused execution and alignment with healthcare providers.
Marc Kikuchi, President & Business Head, North America, stated that the commercialization by Glenmark for RYALTRIS® in the United States is an important step for company growth. He noted that it will strengthen the company’s innovative businesses in the U.S.
RYALTRIS® is approved in key markets including the United States, European Union, United Kingdom, Australia, South Korea, Russia and China. In fiscal year 2026, RYALTRIS® was launched in 11 additional markets, expanding its presence to 55 countries worldwide.
Glenmark Pharmaceuticals Ltd. (BSE: 532296 | NSE: GLENMARK) is a global, research-led pharmaceutical company focused on innovation and accessibility. The company has 11 manufacturing facilities across four continents and six research and development centres, with a commercial presence in over 80 countries.
*Calculated on the anhydrous basis
Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.